4-Hydroxytamoxifen (Afimoxifene)

Name: 4-Hydroxytamoxifen (Afimoxifene)
Brand: Selleck Chemicals
SKU: S7827
Rating: 5 (9 reviews)

For research use only.

Catalog No.S7827 Synonyms: Afimoxifene

9 publications

4-Hydroxytamoxifen (Afimoxifene) Chemical Structure

CAS No. 68392-35-8

4-Hydroxytamoxifen (Afimoxifene) is the active metabolite of tamoxifen and a selective estrogen receptor (ER) modulator that is widely used in the therapeutic and chemopreventive treatment of breast cancer. It activates on-target modification frequency for intein-Cas9 variants.

Selleck's 4-Hydroxytamoxifen (Afimoxifene) has been cited by 9 publications

Nat Methods, 2017, 14(9):891-896

PubMed: 28737741 ( click the link to review the publication )

BMC Dev Biol, 2021, 21(1):4

PubMed: 33517884 ( click the link to review the publication )

Breast Cancer Res, 2021, 23(1):26

PubMed: 33602273 ( click the link to review the publication )

Adv Sci (Weinh), 2020, 7(20):2000157

PubMed: 33101843 ( click the link to review the publication )

Cell Rep, 2020, 30(1):25-36

PubMed: 31914391 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-01174-z

PubMed: 33257837 ( click the link to review the publication )

Cells, 2019, 8(6)

PubMed: 31216647 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.28910

PubMed: 31141164 ( click the link to review the publication )

Oncogene, 2017, 36(16):2255-2264

PubMed: 27748766 ( click the link to review the publication )

1 Customer Review

CDK4/6 inhibitor resistance promotes diminished ER expression and activity. (a and b) Proliferation of MCF-7 and MR cells in the presence of different concentrations of ICI (a) or 4-hydroxytamoxifen (4-OHT) (b) was measured by the alamarBlue assay and plotted as % inhibition of proliferation against log concentration of inhibitor. Each data point represents the average value±s.d. of six replicates obtained in three independent experiments.

Oncogene, 2016, 36(16):2255-2264. 4-Hydroxytamoxifen (Afimoxifene) purchased from Selleck.

Purity & Quality Control

Choose Selective Estrogen/progestogen Receptor Inhibitors

Biological Activity

Description

In vitro

4-OHT is a potent activator of ER and has been shown to have a higher affinity for estrogen receptors compared to tamoxifen. It has significant dose and time-dependent direct effects to alter the contractile function of isolated adult rat cardiac myocytes^[1]. 4-HT activates on-target modification frequency for intein-Cas9 variants ^[3].

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
MCF7 cells	NGrkR\|FRem:uaX\ldoF1cW:wIHHzd4F6			MVfJcohq[mm2aX;uJI9nKGW\|dILv[4VvNXO2aX31cIF1\WRiTVPGMVch[2WubDDwdo9tcW[ncnH0bY9vNCCLQ{WwQVAvPSCwTR?=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek86PTR6OEG3K\|46PTR6OEG3QE9iRg>?
MCF7	M2fHNWZ2dmO2aX;uJIF{e2G7			NVn3foxQTW[oZXP0bZZmKGSxc3Wg[o9zKFt\|SG2tJIV{fHKjZHnvcEBi\2GrboP0JJBzd2yrZnXyZZRqd25ib3[gUWNHNTdiY3XscJMtKEWFNUCgQUAxNjByMECzJO69VS5?	MlTBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd4OU[4NUc,Ojd4OU[4NVww[T5?
MCF7	NEK4WGdHfW6ldHnvckBie3OjeR?=		NFnhdWk1KGi{cx?=	M3vpZmlv\HWldHnvckBw\iCHUnHsdIhiKGSnZ4Lh[IF1cW:wIHnuJIh2dWGwIF3DSlch[2WubIOgbY4heGinbn;sJJJm\CCocnXlJHJRVUlibXXkbZVuKGOxboThbY5qdmdiNTWgZ4hiemOxYXyg[IV5fHKjbj30doVifGWmIF\CV{BqdmO3YnH0[YQh\m:{IESgbJJ{KGK7IGPQNUBidmRiYX70bU1GWiC{YXLibZQhdW:wb3PvcI5idCCjboTpZo9lgSCkYYPl[EBqdi2lZXzsJHdme3Sncn6gZZN{[XluIFHjeIl3cXS7IE2gNE4xODBzIN88UU4>	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB6Nk[yOkc,OzByOE[2NlY9N2F-
MCF7	MmLTSpVv[3Srb36gZZN{[Xl?			NVO2OnpzTW[oZXP0bZZmKGOxbnPlcpRz[XSrb36gZYdicW6\|dDDNR2YuPyCkcnXhd5QhfHWvb4KgZ4VtdHNidYPpcochVUOILUegZZN{[XluIFXDOVAhRSByLkCwNFEzKM7:TT6=	MlXTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJ6MkW5N\|UoRjF{OEK1PVM2RC:jPh?=
MCF7	NV\yeXlESW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			MlywRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|LDDJR\|UxKD1iMD6wNFA2KM7:TT6=	M3v4V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEC1Nlg3Lz5{MkSwOVI5PjxxYU6=
MCF7	M2C3[2FvfGmycn;sbYZmemG2aY\lJIF{e2G7			NWrmdVd[SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzMEBKSzVyIE2gNE4xODB3M{eg{txONg>?	MmfBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ2MEewNVIoRjJ4NEC3NFEzRC:jPh?=
MCF	M1zIeGZ2dmO2aX;uJIF{e2G7			MVPBcpRi\2:waYP0JIFkfGm4aYT5JIF1KHC{b3fld5Rmem:wZTDy[YNmeHSxcjDpckBpfW2jbjDNR2Yh[2WubIOgZZN{\XO\|ZXSgZZMh\XO2cnHkbY9tNWmwZIXj[YQhemWlZYD0c5IhemW\|cH;ud4UtKEmFNUCgQUAxNjByMEe5OFMh\|ryPLh?=	NY[2SGdVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0NFcxOTJpPkK2OFA4ODF{PD;hQi=>
Ishikawa endometrial cells	Ml:wSpVv[3Srb36gZZN{[Xl?			M{jWfmFod26rc4SgZYN1cX[rdImgZZMh[WytYXzpcoUheGixc4DoZZRie2ViaX7keYN1cW:wIHnuJGl{cGmtYYfhJIVv\G:vZYTybYFtKGOnbHzzJINwdXCjcnXkJJRwKEV{LDDFR\|UxKD1iMD6wNFA5KM7:TT6=	NV20[YZxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUWzPFAzODhpPkG1N\|gxOjB6PD;hQi=>
MCF7	MYjGeY5kfGmxbjDhd5NigQ>?			NH\nemtKdmirYnn0bY9vKG:oIHXzeJJw\2WwLXnu[JVk\WRicILvcIln\XKjdHnvckBqdiCqdX3hckBOS0ZvNzDidoVie3RiY3HuZ4VzKGOnbHzzMEBKSzVyIE2gNE4xODFzNzFOwG0v	M1f5bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzlzNUS5OlMoRjlzNUS5OlM9N2F-
MCF7	MWHGeY5kfGmxbjDhd5NigQ>?		NVXTZXJVOjRiaILz	NGDGd21CdnSjZ3;ubZN1KGGldHn2bZR6KGG2IFXSZYxxcGFiaX6gbJVu[W5iTVPGO{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHXzeJJw\2WwLXnu[JVk\WRidILhcpNkemmydHnvckBxemWrbnP1ZoF1\WRib4\ldo5q\2i2IH\vcIxwf2WmIHL5JIV{fHKxZ3XuJIFl\Gm2aX;uJI1m[XO3cnXkJIFnfGW{IEK0JIhzeyCkeTDkeYFtKGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygTWM2OCB;IECuNFA{KM7:TT6=	M4DsSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6Mkm2N\|k5Lz5{OEK5OlM6QDxxYU6=
Rosetta 2 DE3	NF\yOYFHfW6ldHnvckBie3OjeR?=		MmL6NUBpeg>?	M4PSXmRqe3CuYXPlcYVvfCCxZjDbN2heNWW\|dILh[IlwdCCocn;tJJJm[2:vYnnuZY51KGi3bXHuJG4ufGW{bXnuZYwhUGm\|LYTh[4dm\CCHUnHsdIhiKEyERDDoZZJjd3KrbnegR\|M5OVNxQ{SxO3MwSzV\|MGOgcZV1[W62IHX4dJJme3OnZDDpckBTd3OndIThJFIhTEV\|IHPvcZBmfGWwdDDj[YxteyCjZoTldkAyKGi{IHL5JHNRSSCkaX7kbY5oKGG\|c3H5MEBKSzVyIE2gNE4xODRizszNMi=>	NX71NoZtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPVY{QThpPkK4Nlk3Ozl6PD;hQi=>
insect cells	MVXGeY5kfGmxbjDhd5NigQ>?			NFrtXIZKdmirYnn0bY9vKG:oIH\seY9zdW:wZTDFV\|Ih\3KnZX6gZolv\GmwZzD0c{Bz\WOxbXLpcoFvfCCodXzsJIxmdme2aDDoeY1idiCHUnHsdIhiKGW6cILld5Nm\CCrbjDpcpNm[3RiY3XscJMh[nliZnz1c5Jme2OnbnPlJJBwdGG{aYrheIlwdiCjc4PhfUwhUUN3MDC9JFAvODB4Mkmg{txONg>?	M3fXVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{O1NlE1Lz5{OEezOVIyPDxxYU6=
MCF-7-2a	MkfBSpVv[3Srb36gZZN{[Xl?			M3jqPWlvcGmkaYTpc44hd2ZiZYP0doFlcW:uIHnu[JVk\WRiZYP0do9o\W5icnXj[ZB1d3JidILhcpNkemmydHnvcoFtKGGldHn2ZZRqd25iaX6gUWNHNTdvMnGgZ4VtdHNuIFnDOVAhRSByLkCwO{DPxE1w	NF7yXVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMk[3NlI1QSd-MUK2O\|IzPDl:L3G+
MCF7	MlTvRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MY[yOEBpenN?	MorHRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHHmeIVzKDJ2IHjyd{BjgSCPVGOgZZN{[XluIFnDOVAhRSByLkCwPFUh\|ryPLh?=	M3m1NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MkeyNlU3Lz5zOEK3NlI2PjxxYU6=
MCF7	MWXGeY5kfGmxbjDhd5NigQ>?			M1Sxe2lvcGmkaYTvdpkh[2:wY3XueJJifGmxbjDh[4FqdnO2IF3DSk04KGK{ZXHzeEB1fW2xcjDj[YxteyC3c3nu[{BOS0ZvNzDhd5NigSxiSVO1NEA:KDBwMEC4OUDPxE1w	M1\wTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{OEK1PVM2Lz5zMkiyOVk{PTxxYU6=
Ishikawa cells	NEXCPYhHfW6ldHnvckBie3OjeR?=		NH\0SmU4OiCqcoO=	M1\Fd2FvfGGpb37pd5Qh[WO2aY\peJkh[XRiZYP0do9o\W5icnXj[ZB1d3JiYXzwbIEw[mW2YTDpckBpfW2jbjDJd4hqc2G5YTDj[YxteyCjZoTldkA4OiCqcoOgZpkh[WytYXzpcoUheGixc4DoZZRie2ViYYPzZZktKEmFNUCgQUAxNjBzIN88UU4>	M1POWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK2PVMyLz5{OESyOlk{OTxxYU6=
insect cells	M1jq[mZ2dmO2aX;uJIF{e2G7			NIrqVoxFcXOybHHj[Y1mdnRib3[g[ox2d3Knc3PlbY4hdGGkZXzl[EBme3S{YXTpc4wh\nKxbTDoeY1idiC{ZXPvcYJqdmGwdDDFVoJmfGFiZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKGmwc3XjeEBk\WyuczDifUBndHWxcnXzZ4Vv[2VicH;sZZJqgmG2aX;uJIF{e2G7LDDJR\|UxKD1iMD6wNkDPxE1w	MnrpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh6M{WxO\|YoRjF6OEO1NVc3RC:jPh?=
MCF7	NIf2O2REgXSxdH;4bYNqfHliYYPzZZk>		M4LUNVUh\GG7cx?=	MYDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEWg[IF6eyxiSVO1NEA:KDBwMEK5NUDPxE1w	NXPjRol2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OlQ6OjhpPkKzPFY1QTJ6PD;hQi=>
GT1-7	MU\GeY5kfGmxbjDhd5NigQ>?		NHPKVIQzOCC2bzCyOEBpenN?	MUHBcpRi\2:waYP0JIFkfGm4aYT5JIF1KGW\|dILv[4VvKHKnY3XweI9zKGmwIH3veZNmKEeWMT23JINmdGy\|IHjhdoJwemmwZzDi[ZRiNWejbHHjeI9{cWSjc3WgdoVxd3K2ZYKg[4Vv\SCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hOTekZYThMYV{fHKjZHnvcEBqdmS3Y3XkJJJme3CxboPlJI1m[XO3cnXkJIFnfGW{IEKwJJRwKDJ2IHjyd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO\|YYmsJGlEPTBiPTCwMlA{OzJizszNMi=>	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDRyMEKzPUc,Ojh2MECyN\|k9N2F-
insect cells	NVHiWW8zTnWwY4Tpc44h[XO\|YYm=			MVXEbZNxdGGlZX3lcpQhd2ZiZnz1c5Jme2OnaX6gcIFj\WynZDDld5Rz[WSrb3yg[pJwdSCqdX3hckBz\WOxbXLpcoFvfCCHUnHsdIhiKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBqdnOnY4SgZ4VtdHNiYomg[ox2d3Knc3PlcoNmKHCxbHHybZpifGmxbjDhd5NigSxiSVO1NEA:KDBwMESg{txONg>?	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDh\|NUG3Okc,OTh6M{WxO\|Y9N2F-
HEK293	MW\GeY5kfGmxbjDhd5NigQ>?		MXmzNEBucW6\|	MXvJcohq[mm2aX;uJI9nKEeIUD30ZYdo\WRiaIXtZY4hWEyGMjDlfJBz\XO\|ZXSgbY4hcHWvYX6gTGVMOjl\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJJBpd3OyaHH0bYR6dGK3dHHuc4wuY2R7XTDwdo9lfWO2aX;uJIFnfGW{IEOwJI1qdnNiYomgcYF{eyC\|cHXjeJJwdWW2cnnjJIFv[Wy7c3nzMEBKSzVyIE2gNE4xPDRizszNMi=>	NV\B[I5URGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxN\|Y6PzVpPkG5NVM3QTd3PD;hQi=>
HEK293	NVLaV25FTnWwY4Tpc44h[XO\|YYm=		NYnCVYU1OSCqch?=	NX7ZNXllSW62YXfvcol{fCCjY4Tpeol1gSCjdDDy[YNwdWKrbnHueEBpfW2jbjDFVoFteGijIHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCnc4TyZYRqd2xvaX7keYNm\CC\RmCt[pV{\WRiU2LDNUBkd2GldHn2ZZRweiC{ZXPyeYl1dWWwdDDt[YF{fXKnZDDh[pRmeiBzIHjyJIlvKHC{ZYPlcoNmKG:oIFPv[YxmdnSncnH6bY5mKEhiYomgRnJGXCCjc4PhfUwhUUN3MDC9JFAvODdizszNMi=>	M37NOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEe4OlA6Lz5\|MEC3PFYxQTxxYU6=
MCF7	MmHQRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MVO3NkBpenN?	NIj6R3BCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIV{fHKxZ3XuJJJm[2WydH;yJIRmeGWwZHXueEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlExPyEQvF2u	NYD3c3NURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi4N\|UyPzZpPkG4PFM2OTd4PD;hQi=>
MCF7	NHnNeo5CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MUK3NkBpenN?	NVO4b2xHSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTD0dplx[W5iYnz1[UBie3OjeTygS2k2OCB;IECuNVA4KM7:TT6=	NYrnS2JYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3N\|U5OjlpPkKzO\|M2QDJ7PD;hQi=>
MCF7	NYTXTpJVSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NHzIU5o4OiCqcoO=	MYnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IFXSMYRmeGWwZHXueEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlEyKM7:TT6=	MoDuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2Mk[5N\|EoRjJ6NEK2PVMyRC:jPh?=
T47D	M3z2e2N6fG:2b4jpZ4l1gSCjc4PhfS=>		NVfUNZh4PSCmYYnz	NEHufpREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBVPDeGIHPlcIx{KGGodHXyJFUh\GG7czygTWM2OCB;IECuNlEh\|ryPLh?=	NFzJdJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i2OFkzQCd-MkO4OlQ6Ojh:L3G+
Ishikawa endometrial cells	M4nkfGZ2dmO2aX;uJIF{e2G7			MUDBcpRi\2:waYP0JIFkfGm4aYT5JIF{KGmwaHnibZRqd25ib3[gNUBvVSBzNz3i[ZRiNWW\|dILh[IlwdCC\|dHnteYxifGWmIHHsb4FtcW6nIIDoc5NxcGG2YYPlJIlv\HWldHnvckBqdiCLc3jpb4F4[SCnbnTvcYV1emmjbDDj[YxteyxiSVO1NEA:KDBwNUGg{txONg>?	MnfmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV\|OECyNFgoRjF3M{iwNlA5RC:jPh?=
CV1	M{LrUWZ2dmO2aX;uJIF{e2G7		NIDPXWs1PSCqcoO=	NGrHWGtKdn[ncoPlJIFod26rc4SgZYN1cX[rdImgZZQhT0GOND3EUmEh[mmwZHnu[{Bld22jaX6t[pV{\WRibX;1d4UhTVKUZ3HtcYEhdGmpYX7kJIJqdmSrbneg[I9u[WmwIHX4dJJme3OnZDDpckBC\nKrY3HuJIdz\WWwIH3vcotmgSCFVkGgZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4hemWlZYD0c5IhfHKjboPjdolxfGmxbnHsJIFkfGm4aYT5JIFnfGW{IES1JIhzeyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEmFNUCgQUAxNjZizszNMi=>	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDF6OUO5N{c,OjhzOEmzPVM9N2F-
CV1	NYX3c4ZkTnWwY4Tpc44h[XO\|YYm=		MnLjOFUhcHK\|	MnO2TY53\XK\|ZTDh[49vcXO2IHHjeIl3cXS7IHH0JGdCVDRvRF7BJIJqdmSrbneg[I9u[WmwLX\1d4VlKGi3bXHuJGVTWmKndHGgcIlo[W6mIHLpcoRqdmdiZH;tZYlvKGW6cILld5Nm\CCrbjDB[pJq[2GwIHfy[YVvKG2xbnvlfUBEXjFiY3XscJMh[XO\|ZYPz[YQh[XNiZHXjdoVie2ViaX6gdoVk\XC2b4KgeJJidnOlcnnweIlwdmGuIHHjeIl3cXS7IHHmeIVzKDR3IHjyd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO\|YYmsJGlEPTBiPTCwMlY2KM7:TT6=	NEP2[Gc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEG4PVM6Oyd-MkixPFk{QTN:L3G+
HEK293	NWXGd4dJTnWwY4Tpc44h[XO\|YYm=			NFn1[W1C\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJIV{fHKxZ3XuJJJmdGG2ZXSgdoVk\XC2b4Kg[4FudWFiZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEmFNUCgQUAyNjN3IN88UU4>	NETpWVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOwOVY5QCd-MkWzNFU3QDh:L3G+
MCF7	NXjJV\|hKSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M3;5OFQ5KGi{cx?=	MYLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiZYjwdoV{e2mwZzDld5Rzd2enbjDy[YNmeHSxcjDpcoN2[mG2ZXSge4l1cCByLkCwN{BvVSCxZjDld5Rz[WSrb3ygZY5lKDBwMEGgcm0hd2ZidHXzeI9{fGW{b37lJIFnfGW{IES4JIhzeyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6KGmwIIDy[ZNmdmOnIH;mJFUmKG[ndHHsJIJwfmmwZTDz[ZJ2dSxiR1m1NEA:KDFwNEGyOVQh\|ryPLh?=	MlrHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3MUOyO\|UoRjJzNUGzNlc2RC:jPh?=
MCF7	M{Dsd2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		MWq0PEBpenN?	NUi1TXZxSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIV5eHKnc4Ppcoch\XO2cn;n[Y4hemWlZYD0c5IhcW6ldXLheIVlKHerdHigNE4xPiCwTTDv[kBme3S{YXTpc4wh[W6mIECuNFchdk1ib3[geIV{fG:\|dHXyc45mKGGodHXyJFQ5KGi{czDifUB{fWyob4Loc4RidWmwZTDCJIF{e2G7IHnuJJBz\XOnbnPlJI9nKG[ndHHsJIJwfmmwZTDz[ZJ2dSCjbnSgUpVU\XK3bTygS2k2OCB;IEGuPVA2PDZizszNMi=>	NYr4SWRIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG1NVMzPzVpPkKxOVE{Ojd3PD;hQi=>
HeLa	MlP4SpVv[3Srb36gZZN{[Xl?		M4TuTlQvPSCqcoO=	NGfBRohKdmirYnn0bY9vKG:oIFXic4xifmm{dYOg[4x6[2:ycn;0[YlvN22jdILpfEBxem:2ZXnuJHZRPDBiZX70dpkhcW5iaIXtZY4hUGWOYTDj[YxteyCjZoTldkA1NjViaILzJIJmfGFvbHHjeIFu[XOnIILldI9zfGW{IHHzd4F6NCCLQ{WwJF0hOS57NjFOwG0v	M4jTXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NkK0N\|g4Lz5{OU[yOFM5PzxxYU6=
MDA-MB-231	NHjDV2xEgXSxdH;4bYNqfHliYYPzZZk>		NYPNcHBYPCCmYYnz	MXTDfZRwfG:6aXPpeJkh[WejaX7zeEBGWiCwZXfheIl3\SCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJJRz\WG2ZXSg[ZZmenliMjDkZZl{KG[xcjC0JIRigXNibXXhd5Vz\WRiYX\0[ZIhPyCmYYnzJIJ6KEOnbHzUbZRmei2JbH:gcJVucW6nc3PlcoNmKGG\|c3H5MEBKSzVyIE2gNk42KM7:TT6=	MmnaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByN{i2NFkoRjNyMEe4OlA6RC:jPh?=
MCF7	Mn3TRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?			M{WydWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDhd5Nme3OnZDDhd{BqdmOxcoDvdoF1cW:wIH;mJHtu\XSqeXytN2hefGi7bXnkbY5mKGmwdH:gZ4VtdHWuYYKgSG5CKGmwIIPldpVuKG[{ZXWgcYVlcXWvIHnuJIlvKGGkc3XuZ4Uhd2ZiNj6yJJVoN22OIGLOZZNmKDFuIFnDOVAhRSB{Lkeg{txONg>?	M4LtbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NkGxOFc5Lz5{Mk[xNVQ4QDxxYU6=
MCF7	NIPLVpZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MX63NkBpenN?	NV;qOlJXSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCyMlc6KM7:TT6=	NULLdpdkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[4PVY4ODZpPkK2PFk3PzB4PD;hQi=>
MCF12A	MYLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MmrZOFghcHK\|	M2ji[WFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4Sg[ZN1em:pZX6gdoVk\XC2b4Kt[IVncWOrZX70JIh2dWGwIF3DSlEzSSClZXzsd{BqdmO3YnH0[YQhf2m2aDCxNFAhdk1ib3[g[ZN1emGmaX;sJIFv\CByLkC3JI5OKG:oIITld5Rwe3Sncn;u[UBi\nSncjC0PEBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSCrbjDwdoV{\W6lZTDv[kBn\XSjbDDic5ZqdmVic3XyeY0h[W6mIF71V4VzfW1uIFfJOVAhRSB\|LkKzOVk1KM7:TT6=	MkD2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3MUOyO\|UoRjJzNUGzNlc2RC:jPh?=
MCF7	NFzaN\|ZEgXSxdH;4bYNqfHliYYPzZZk>		M3X3SFQh\GG7cx?=	MYXDfZRwfG:6aXPpeJkh[WejaX7zeEBGWiCyb4PpeIl3\SCqdX3hckBOS0Z5IHPlcIx{KHS{ZXH0[YQh\X[ncomgNkBl[Xm\|IH\vdkA1KGSjeYOgcYVie3W{ZXSgZYZ1\XJiNzDkZZl{KGK7IFPlcIxVcXSncj3HcI8hdHWvaX7ld4NmdmOnIHHzd4F6NCCLQ{WwJF0hOy5\|IN88UU4>	Mnn0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByN{i2NFkoRjNyMEe4OlA6RC:jPh?=
MCF12A	Mn;NRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NVn3[ZRFPDhiaILz	MorxRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDld5Rzd2enbjDy[YNmeHSxcj3k[YZq[2mnboSgbJVu[W5iTVPGNVJCKGOnbHzzJIlv[3WkYYTl[EB4cXSqIECuNFA{KG6PIH;mJIV{fHKjZHnvcEBidmRiMD6wNUBvVSCxZjD0[ZN1d3O2ZYLvcoUh[W[2ZYKgOFghcHK\|IHL5JJN2dG[xcnjv[IFucW6nIFKgZZN{[XliaX6gdJJme2WwY3Wgc4YhPSViZnX0ZYwh[m:4aX7lJJNmenWvLDDHTVUxKD1iMz6zNVE{OSEQvF2u	Mo\pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3MUOyO\|UoRjJzNUGzNlc2RC:jPh?=
MCF7	M3P2fWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NHXFZlQ1QCCqcoO=	MnHjRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHX4dJJme3Orbneg[ZN1em:pZX6gdoVk\XC2b4KgbY5kfWKjdHXkJJdqfGhiMUCwJI5OKG:oIHXzeJJi\GmxbDDhcoQhOC5yNzDuUUBw\iC2ZYP0c5N1\XKxbnWgZYZ1\XJiNEigbJJ{KGK7IIP1cIZwemixZHHtbY5mKEJiYYPzZZkhcW5icILld4Vv[2Vib3[g[oV1[WxiYn;2bY5mKHOncoXtJIFv\CCQdWPldpVuNCCJSUWwJF0hOy52NkezO{DPxE1w	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTVzM{K3OUc,OjF3MUOyO\|U9N2F-
MDA-MB-231	M1n6T2N6fG:2b4jpZ4l1gSCjc4PhfS=>		MXm0JIRigXN?	NUX4XmZsS3m2b4TvfIlkcXS7IHHnZYlve3RiRWKgcoVo[XSrdnWgbJVu[W5iTVTBMW1DNTJ\|MTDj[YxteyC2cnXheIVlKGW4ZYL5JFIh\GG7czDmc5IhPCCmYYnzJI1m[XO3cnXkJJBwe3RibHHzeEBld3OnIHL5JGNmdGyWaYTldk1IdG9ibIXtbY5me2OnbnPlJIF{e2G7LDDJR\|UxKD1iMz61JO69VS5?	MoTLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByN{i2NFkoRjNyMEe4OlA6RC:jPh?=
MCF12A	M{DVOWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NVnCVJN[PDhiaILz	MYfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHXzeJJw\2WwIILlZ4VxfG:{LXTl[olkcWWwdDDoeY1idiCPQ1[xNmEh[2WubIOgbY5kfWKjdHXkJJdqfGhiMD6wOkBvVSCxZjDld5Rz[WSrb3ygZY5lKDBwMEegcm0hd2ZidHXzeI9{fGW{b37lJIFnfGW{IES4JIhzeyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6KGmwIIDy[ZNmdmOnIH;mJIZmfGGuIHLveolv\SC\|ZYL1cUBidmRiToXT[ZJ2dSxiR1m1NEA:KDNwOEmwOFUh\|ryPLh?=	NY[0TZdERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG1NVMzPzVpPkKxOVE{Ojd3PD;hQi=>
MCF7	M1HEZWN6fG:2b4jpZ4l1gSCjc4PhfS=>		MmfyOEBl[Xm\|	NVuwVGZUS3m2b4TvfIlkcXS7IHHnZYlve3RiRWKgdI9{cXSrdnWgbJVu[W5iTVPGO{Bk\WyuczD0doVifGWmIHX2[ZJ6KDJiZHH5d{Bnd3JiNDDkZZl{KG2nYYP1doVlKHCxc4SgcIF{fCCmb4PlJIJ6KEOnbHzUbZRmei2JbH:gcJVucW6nc3PlcoNmKGG\|c3H5MEBKSzVyIE2gN{46KM7:TT6=	Mmf0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByN{i2NFkoRjNyMEe4OlA6RC:jPh?=
MCF7	NFqwVHJHfW6ldHnvckBie3OjeR?=			MlvvTY5pcWKrdH;yfUBi[3Srdnn0fUBi\2GrboP0JJBzd2yrZnXyZZRqd25ib3[gUWNHNTdiY3XscJMhcW5icILld4Vv[2Vib3[gNVBmNTZiTTDjc45k\W62cnH0bY9vKG:oIGuzTH0uKGW\|dILh[IlwdCBqRUKpMEBKSzNyIE2gOEDPxE1w	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzZ7NkixK\|4zPzZ7NkixQE9iRg>?
MCF10A	M3K1XmN6fG:2b4jpZ4l1gSCjc4PhfS=>		Mnr5OEBl[Xm\|	M4\LdmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEWUIH7l[4F1cX[nIHj1cYFvKE2FRkGwRUBk\WyuczD0doVifGWmIHX2[ZJ6KDJiZHH5d{Bnd3JiNDDkZZl{KG2nYYP1doVlKHCxc4SgcIF{fCCmb4PlJIJ6KEOnbHzUbZRmei2JbH:gcJVucW6nc3PlcoNmKGG\|c3H5MEBKSzVyIE2gOEDPxE1w	NEDjZnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEC3PFYxQSd-M{CwO\|g3ODl:L3G+
MCF10A	NWjkXnk1S3m2b4TvfIlkcXS7IHHzd4F6		MYq0JIRigXN?	MlP5R5l1d3SxeHnjbZR6KGGpYXnud5QhTVJibnXnZZRqfmViaIXtZY4hVUOIMUDBJINmdGy\|IITy[YF1\WRiZY\ldpkhOiCmYYnzJIZweiB2IHThfZMhdWWjc4Xy[YQh[W[2ZYKgO{Bl[Xm\|IHL5JGNmdGyWaYTldk1IdG9ibIXtbY5me2OnbnPlJIF{e2G7LDDJR\|UxKD1iNDFOwG0v	NWPNWWpkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwO\|g3ODlpPkOwNFc5PjB7PD;hQi=>
yeast cells	M4DyPWFvfGmnc4Tyc4dmdmmlIHHzd4F6			M4G4fmFvfGmnc4Tyc4dmdmmlIHHjeIl3cXS7IHH0JIV{fHKxZ3XuJJJm[2WydH;yJIFteGijIHX4dJJme3OnZDDpckB6\WG\|dDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKDF5LXLleIEu\XO2cnHkbY9tNWmwZIXj[YQh[mW2YT3nZYxi[3Sxc3nkZZNmKGGldHn2bZR6KGK7IIT3c{BpgWK{aXSgZZN{[XluIFnDOVAhRSB2LkSg{txONg>?	M{XncFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4NESxNFg3Lz5zNkS0NVA5PjxxYU6=
NCI-ADR-RES	NF7VeWlCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NGD0Vos1QCCqcoO=	NXrjPGZXSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBme3S{b3flckBz\WOncITvdk1l\W[rY3nlcpQhcHWvYX6gUmNKNUGGUj3SSXMh[2WubIOgbY5kfWKjdHXkJJdqfGhiMD6wNFMhdk1ib3[g[ZN1emGmaX;sJIFv\CByLkCxJI5OKG:oIITld5Rwe3Sncn;u[UBi\nSncjC0PEBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSCrbjDwdoV{\W6lZTDv[kA2LSCoZYThcEBjd3[rbnWgd4VzfW1uIFfJOVAhRSB2LkS2Olg1KM7:TT6=	MnfTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3MUOyO\|UoRjJzNUGzNlc2RC:jPh?=
BT-20	M{PiXWZ2dmO2aX;uJIF{e2G7	NILqNVYyOCEQvF2=		MmjuTY5pcWKrdH;yfUBi[3Srdnn0fUBi\2GrboP0JJBzd2yrZnXyZZRqd25ib3[gRnQuOjBiY3XscJMhcW5icILld4Vv[2Vib3[gWHBGKGG2IEGw[U02KE1iY3;uZ4VvfHKjdHnvckwhUUN\|MDC9JFQvQCEQvF2u	M1nrclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5Nkm2PFEoRjJ5Nkm2PFE9N2F-
Calu-1	M{K5cWZ2dmO2aX;uJIF{e2G7		Mlu2N\|AhdWmwcx?=	MoDZTY5pcWKrdHnvckBw\iCSTFSxJIlvKGi3bXHuJGNidHVvMTDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckBxcG:\|cHjheIllgWykdYThco9tNVumOW2gdJJw\HWldHnvckBi\nSncjCzNEBucW6\|IHL5JI1ie3Nic4DlZ5Rzd22ndILpZ{BidmGueYPpd{whUUN3MDC9JFQvQCEQvF2u	MorZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzM{[5O\|UoRjF7MUO2PVc2RC:jPh?=
MCF7	M{CydGZ2dmO2aX;uJIF{e2G7			MWjBcpRi\2:waYP0JIFkfGm4aYT5JIF1KEWUYXzwbIEhemWlZYD0c5IhcW5iaIXtZY4hVUOINzDj[YxteyxiSVO1NEA:KDRwOEm3O\|kh\|ryPLh?=	NGOye2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkSwO\|AyOid-Mk[0NFcxOTJ:L3G+
MDA-MB-231	NFGyPFhCdnSrY3HuZ4VzKGG\|c3H5		NWjLWFdiPDhiaILz	MYXBcpRq[2GwY3XyJIFo[Wmwc4SgbJVu[W5iRWKtdI9{cXSrdnWgUWRCNU2ELUKzNUBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDJR\|UxKD1iNT60JO69VS5?	NGTWcXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlE1PSd-MkS5OFYyPDV:L3G+
MCF-7	MWjDfZRwfG:6aXPpeJkh[XO\|YYm=			MlTFR5l1d3SxeHnjbZR6KGGpYXnud5QhVUOILUegZ4VtdHNiaX6geIhmKGGkc3XuZ4Uhd2ZiMTD1UUBGOiBqZYP0doFlcW:uKTygR5l1d3SxeHnjbZR6KD1iNjFOwG0v	M{X2WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzlyOEmzN\|IoRjlyOEmzN\|I9N2F-
NCI-ADR-RES	NHLHR2JCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		Mn63OFghcHK\|	MWPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHXzeJJw\2WwIILlZ4VxfG:{LXTl[olkcWWwdDDoeY1idiCQQ1mtRWRTNVKHUzDj[YxteyCrbnP1ZoF1\WRid3n0bEAxNjB4IH7NJI9nKGW\|dILh[IlwdCCjbnSgNE4xPyCwTTDv[kB1\XO2b4P0[ZJwdmViYX\0[ZIhPDhiaILzJIJ6KHO3bH\vdohw\GGvaX7lJGIh[XO\|YYmgbY4heHKnc3XuZ4Uhd2ZiZnX0ZYwh[m:4aX7lJJNmenWvIHHu[EBPfVOncoXtMEBIUTVyIE2gOk4yPjV7NTFOwG0v	M3rVelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNUGzNlc2Lz5{MUWxN\|I4PTxxYU6=
AU565	NVnKbY5MSW62aXPhcoNmeiCjc4PhfS=>		MoPqOFghcHK\|	MmHPRY51cWOjbnPldkBi\2GrboP0JIh2dWGwIFXSMY5m\2G2aY\lJGFWPTZ3IHPlcIx{KGG\|c3Xzd4VlKGG\|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUA3NjJizszNMi=>	NGrxOng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlE1PSd-MkS5OFYyPDV:L3G+
MCF7L	NGiz[FFCdnSrY3HuZ4VzKGG\|c3H5		MXm0PEBpenN?	MVnBcpRq[2GwY3XyJIFo[Wmwc4SgbJVu[W5iRWKtdI9{cXSrdnWgUWNHP0xiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK\|IHL5JHNTSiCjc4PhfUwhUUN3MDC9JFYvOyEQvF2u	NV;xUXBGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFYyPDVpPkK0PVQ3OTR3PD;hQi=>
SKOV3-MDR1-M6/6	NFzFWJlCdnSrY3HuZ4VzKGG\|c3H5		NHLmOlk1QCCqcoO=	NFzSOY5CdnSrY3HuZ4VzKGGpYXnud5QhcHWvYX6gV2tQXjNvTVTSNU1OPi94IHPlcIx{KGG\|c3Xzd4VlKGG\|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUA3NjR7IN88UU4>	MmfjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[xOFUoRjJ2OUS2NVQ2RC:jPh?=
MCF7	MljyRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MmToNlQhcHK\|	NYO5XpRtSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTC3MlIh\|ryPLh?=	MkDCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzOEmwOVUoRjJ2MUi5NFU2RC:jPh?=
SKOV3	M4\PdWFvfGmlYX7j[ZIh[XO\|YYm=		MmLLOFghcHK\|	NUjQemJnSW62aXPhcoNmeiCjZ3HpcpN1KGi3bXHuJHNMV1Z\|IHPlcIx{KG:4ZYLlfJBz\XO\|aX7nJHAu\3BiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiSVO1NEA:KDdwNE[g{txONg>?	NWPvO2VzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFYyPDVpPkK0PVQ3OTR3PD;hQi=>
PC3	NHvrR2VCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M4DXU\|Q5KGi{cx?=	NYPWc\|h3SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBidmS{b3flckBz\WOncITvdk1l\W[rY3nlcpQhcHWvYX6gVGM{KGOnbHzzJIlv[3WkYYTl[EB4cXSqIECuOkBvVSCxZjDld5Rz[WSrb3ygZY5lKDBwNzDuUUBw\iC2ZYP0c5N1\XKxbnWgZYZ1\XJiNEigbJJ{KGK7IIP1cIZwemixZHHtbY5mKEJiYYPzZZktKEeLNUCgQUA4NjV6NUe4JO69VS5?	M{P6TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNUGzNlc2Lz5{MUWxN\|I4PTxxYU6=
NCI-ADR-RES	NWPXRYc6SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NYrLdG4yPDhiaILz	M{\aemFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4Sg[ZN1em:pZX6gdoVk\XC2b4Kt[IVncWOrZX70JIh2dWGwIF7DTU1CTFJvUlXTJINmdGy\|IHnuZ5Vj[XSnZDD3bZRpKDFyMDDuUUBw\iCnc4TyZYRqd2xiYX7kJFAvODdibl2gc4YhfGW\|dH;zeIVzd26nIHHmeIVzKDR6IHjyd{BjgSC\|dXzmc5Jpd2SjbXnu[UBDKGG\|c3H5JIlvKHC{ZYPlcoNmKG:oIH\leIFtKGKxdnnu[UB{\XK3bTDhcoQhVnWVZYL1cUwhT0l3MDC9JFcvPzZ{NEeg{txONg>?	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTVzM{K3OUc,OjF3MUOyO\|U9N2F-
MCF-7	MWjDfZRwfG:6aXPpeJkh[XO\|YYm=			M4\NOmN6fG:\|dHH0bYNqfHliYXfhbY5{fCCPQ1[tO{Bk\WyuczDpckB1cGVicILld4Vv[2Vib3[gNUB2VW:uYYKgSVIhMGW\|dILh[IlwdCluIFnDOVAhRSB6IN88UU4>	M3[1WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzlyOEmzN\|IoRjlyOEmzN\|I9N2F-
LNCAP	MVTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MkjIOFghcHK\|	NU[zTHpSSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDMUmNCWCClZXzsd{BmgHC{ZYPzbY5oKGGwZILv[4VvKHKnY3XweI9zKGmwY4XiZZRm\CC5aYToJFAvPiCwTTDv[kBme3S{YXTpc4wh[W6mIECuO{BvVSCxZjD0[ZN1d3O2ZYLvcoUh[W[2ZYKgOFghcHK\|IHL5JJN2dG[xcnjv[IFucW6nIFKgZZN{[XluIFfJOVAhRSB6LkOxO\|Y1KM7:TT6=	NVXBcY1PRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG1NVMzPzVpPkKxOVE{Ojd3PD;hQi=>
MCF7	NYfDZ21ZSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NXjIcm9oPSCmYYnz	NGLpOnFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiNTDkZZl{KGK7IGfTWE05KGG\|c3H5MEBKSzVyIE2gPE46KM7:TT6=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZzNEGxPEc,OjV4MUSxNVg9N2F-
MCF7	MkLhRY51cWOjbnPldkBie3OjeR?=		NEfHVXY1QCCqcoO=	NI\ZO4tCdnSrY3HuZ4VzKGGpYXnud5QhcHWvYX6gSXIueG:\|aYTpeoUhVUOINzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hQS5{IN88UU4>	NXy5eHFxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFYyPDVpPkK0PVQ3OTR3PD;hQi=>
MCF-7	M1HtOWN6fG:2b4jpZ4l1gSCjc4PhfS=>			MUHDfZRwfG:6aXPpeJkh[WejaX7zeEBOS0ZvNzDj[YxteyCrbjDwdoV{\W6lZTDv[kAyKHWPIFWyJEhme3S{YXTpc4wqNCCFeYTveI95cWOrdImgQUA6NjRizszNMi=>	NWGwfmFtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxOUC4PVM{Oid-OUC4PVM{OjxxYU6=
MDA-MB-231	MWnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M3uyT\|I1KGi{cx?=	MYfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[W[2ZYKgNlQhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFExNjRizszNMi=>	NIrsc3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG4PVA2PSd-MkSxPFkxPTV:L3G+
MDA-MB-453	NFLmSGhCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NXTp[mo{PzJiaILz	NYOx[WdSSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNEWzJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSBzMD60JO69VS5?	NUPDd2FJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1NFY2QDJpPkK4OVA3PTh{PD;hQi=>
DU145	MUPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		Mm[4OFghcHK\|	NH7UZYhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIFv\HKxZ3XuJJJm[2WydH;yMYRm\mmlaXXueEBpfW2jbjDEWVE1PSClZXzsd{BqdmO3YnH0[YQhf2m2aDCwMlYhdk1ib3[g[ZN1emGmaX;sJIFv\CByLkegcm0hd2ZidHXzeI9{fGW{b37lJIFnfGW{IES4JIhzeyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6NCCJSUWwJF0hOTBwN{G1NkDPxE1w	NYTvZ5pmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG1NVMzPzVpPkKxOVE{Ojd3PD;hQi=>
MCF7	M1PqVmN6fG:2b4jpZ4l1gSCjc4PhfS=>		M{D4NlQ5KGi{cx?=	M3fYcGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFE{NjZizszNMi=>	NVL6Z3R2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NVg2QTVpPkK1OlE5PTl3PD;hQi=>
Vero	NGDXbmRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M2TUVFczKGi{cx?=	MnnhRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDh[pJq[2GwIHfy[YVvKG2xbnvlfUBX\XKxIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yh[2WubDD2bYFjcWyrdImgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEG1MlEh\|ryPLh?=	M2jqblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUmzNlY6Lz5{NUm5N\|I3QTxxYU6=
DU145	M4rye2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		M{\uPFczKGi{cx?=	NGDKV5NCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDF3LkOg{txONg>?	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl7M{K2PUc,OjV7OUOyOlk9N2F-
MCF7	NGjQNGdCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NH7aTVc4OiCqcoO=	M1X6NWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMUWuOkDPxE1w	NXjsPZZMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1NFY2QDJpPkK4OVA3PTh{PD;hQi=>
MCF7	NV2weoRHSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M2nMVVczKGi{cx?=	NIK5[HRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOTVwNjFOwG0v	NIXUdnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm5N\|I3QSd-MkW5PVMzPjl:L3G+
MDA-MB-231	NEHvN2pCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M1[0TFczKGi{cx?=	Mor1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAzOC5zIN88UU4>	M{\wU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NUC2OVgzLz5{OEWwOlU5OjxxYU6=
MCF7	M13JcmFvfGmycn;sbYZmemG2aY\lJIF{e2G7	MVWwMlYzPSCwTR?=	NGnEO\|kzPCCqcoO=	MlrPRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHH0JFAvPjJ3IH7NJIFnfGW{IEK0JIhzeyCkeTDNWHMh[XO\|YYm=	NYLXcFBFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiyO\|IzPTZpPkG4NlczOjV4PD;hQi=>
MCF7	MXHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?	MmG4NE43OjVidH:gNVAhdk1?	M{KyWFI1KGi{cx?=	M3zkbmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDheEA,OC54MkWgeI8hOTBibl2gZYZ1\XJiMkSgbJJ{KGK7IF3UV{Bie3OjeR?=	MmfoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh{N{KyOVYoRjF6MkeyNlU3RC:jPh?=
MCF7:WS8	M2XiV2Z2dmO2aX;uJIF{e2G7			NFyxSZpC[3SrdnH0bY9vKG:oIHj1cYFvKEWUIHnuJIh2dWGwIF3DSlc7X1N6IHPlcIx{KGW6cILld5NqdmdiZYP0do9o\W5icnXzdI9ve2m4ZTDlcIVu\W62IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigQ>?	M17N[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyM{O0N\|Y5Lz5{MEOzOFM3QDxxYU6=
MCF7:WS8	NXnxU\|FrSW62aXXzeJJw\2WwaXOgZZN{[Xl?	NX7sV5c1OSC3TR?=	NUfx[HpqPyCmYYnz	MkfhRY51cWW\|dILv[4VvcWNiYXP0bZZqfHliaX6gbJVu[W5iRWLhcJBp[SCneIDy[ZN{cW6pIF3DSlc7X1N6IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yh\XO2cnHkbY9tNWmwZIXj[YQheHKxbHnm[ZJifGmxbjDheEAyKHWPIHHmeIVzKDdiZHH5dy=>	M1\mdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyM{O0N\|Y5Lz5{MEOzOFM3QDxxYU6=
MCF7	NGnJTGxCdnSrZYP0do9o\W6rYzDhd5NigQ>?			MYrBcpRq\XO2cn;n[Y5q[yCjY4Tpeol1gSCrbjDoeY1idiCPQ1[3JINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiZYP0doFlcW:uLYP0bY12dGG2ZXSgdJJwdGGldHnuJIdmdmViZYjwdoV{e2mxbh?=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODN\|NEO2PEc,OjB\|M{SzOlg9N2F-
MCF7	MlrZRY51cWW\|dILv[4VvcWNiYYPzZZk>			NWXvTpg3SW62aXXzeJJw\2WwaXOgZYN1cX[rdImgbY4hcHWvYX6gUWNHPyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJIV{fHKjZHnvcE1{fGmvdXzheIVlKHC{b3zp[oVz[XSrb36=	M2rj[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyM{O0N\|Y5Lz5{MEOzOFM3QDxxYU6=
T47D:C:4:2	MYDGeY5kfGmxbjDhd5NigQ>?			MXfFd5Rzd2enbnnjJIFkfGm4aYT5JIF1KHerbHSgeJlx\SCHUjDhcJBp[SCneIDy[ZN{\WRiaX6gWFQ4TDqFOkS6NkBk\WyuczDjc4V5eHKnc4Ppcoch\XO2cn;n[Y4hemW\|cH;ud4Uh\WynbXXueEBjgSCmdXXsJIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigQ>?	MlfEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB\|M{SzOlgoRjJyM{O0N\|Y5RC:jPh?=
MDA-MB-231	NWjibVR3S3m2b4TvfIlkcXS7IHHzd4F6		MlfMN{Bl[Xm\|	Mnz1R5l1d3O2YYTpZ{Bi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYX\0[ZIhOyCmYYnzJIJ6KG2rY4LveIl1\XJiYYPzZZk>	M1\hXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNUm4OVU2Lz5{MEW5PFU2PTxxYU6=
T47D:C:4:2	NYnM[2JUTnWwY4Tpc44h[XO\|YYm=			NX71N\|ZOTXO2cn;n[Y5q[yCjY4Tpeol1gSCjdDD3bYxlKHS7cHWgSXIh[WyyaHGgSFM2OUdibYX0ZY51KGW6cILld5Nm\CCrbjDUOFdFQkN8NEqyJINmdGy\|IHPv[ZhxemW\|c3nu[{Bme3S{b3flckBz\XOyb37z[UBmdGWvZX70JIJ6KGS3ZXygcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6	M{TvbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyM{O0N\|Y5Lz5{MEOzOFM3QDxxYU6=
MCF7	MWHGeY5kfGmxbjDhd5NigQ>?	NWPjRWlmOSEQvF2=	M{XiWFYh\GG7cx?=	M4HiZWRzfWdidYD0ZYtmKGmwIHj1cYFvKE2FRkegZ4VtdHNiYYSgNVAoNTZiTTDh[pRmeiB4IHThfZMh[nliSGDMR{1OWy:PUzDhcoFtgXOrcx?=	M3iwZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OE[0PVI5Lz5{M{i2OFkzQDxxYU6=
MCF7	M4P4W2Z2dmO2aX;uJIF{e2G7	MYqxNEB2VQ>?	MkDsOkBpenN?	MVjVdJJm\3WuYYTpc44hd2ZiRWLhcJBp[SCycn;0[YlvKGyndnXsd{BqdiCqdX3hckBOS0Z5IHPlcIx{KGG2IEGwJJVOKGGodHXyJFYhcHK\|IHL5JHdme3Sncn6gZoxwfCCvZYToc4Q>	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN\|Mk[zNEc,OjR\|M{K2N\|A9N2F-
MCF7:WS8	MlzTSpVv[3Srb36gZZN{[Xl?	NIG3VXQyKM7:TR?=	NF7YZmI1QCCqcoO=	M3W4S2Fod26rc4SgZYN1cX[rdImgZZQhTVJiaX6gbJVu[W5iTVPGO\|pYWzhiY3XscJMh[XO\|ZYPz[YQh[XNicGOyJIdmdmViZYjwdoV{e2mxbjDheEAyOCdvNjDNJIFnfGW{IES4JIhzeyCkeTDSWE1RS1JiYX7hcJl{cXN?	M2HuflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEC1NVk6Lz5{NEiwOVE6QTxxYU6=
MCF7:WS8	NF2yRpNHfW6ldHnvckBie3OjeR?=	NFjpd3QyKM7:TR?=	MVe0PEBpenN?	NWHQ[5ExSWexbnnzeEBi[3Srdnn0fUBifCCHUjDpckBpfW2jbjDNR2Y4QleVODDj[YxteyCjc4Pld5Nm\CCjczDHVmVDOSCpZX7lJIV5eHKnc4Ppc44h[XRiMUCnMVYhVSCjZoTldkA1QCCqcoOgZpkhWlRvUFPSJIFv[Wy7c3nz	NELK[I09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEiwOVE6QSd-MkS4NFUyQTl:L3G+
GH3	MUnGeY5kfGmxbjDhd5NigQ>?	NF7reFIyKM7:TR?=	M172blQ5KGi{cx?=	MYTBcpRi\2:waYP0JIFkfGm4aYT5JIF1KEWUIHnuJJJifCCJSEOgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCnc4TyZYRqd2xvaX7keYNm\CCycn;sZYN1cW5iZ3Xu[UBmgHC{ZYPzbY9vKGG2IEGwK{03KE1iYX\0[ZIhPDhiaILzJIJ6KFKWLWDDVkBidmGueYPpdy=>	NIrqWYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEiwOVE6QSd-MkS4NFUyQTl:L3G+
GH3	M1P3eGZ2dmO2aX;uJIF{e2G7	M1fNclAvOSCwTTD0c{AyKM7:TR?=	MXu0PEBpenN?	M3HOUWFvfGGpb37pd5Qh[WO2aY\peJkh[XRiRWKgbY4hemG2IFfIN{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHXzeJJi\GmxbD3pcoR2[2WmIIDyc4xi[3SrbjDn[Y5mKGW6cILld5Nqd25iYYSgNVAoNTFyIITvJFExLy14IF2gZYZ1\XJiNEigbJJ{KGK7IGLUMXBEWiCjbnHsfZNqew>?	NIHENZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEiwOVE6QSd-MkS4NFUyQTl:L3G+
MCF7	MlzQRY51cWOjbnPldkBie3OjeR?=	MnPENlUxKHSxIEWwNEBvVQ>?	M37mVlUh\GG7cx?=	M4jMd2FvfGmlYX7j[ZIh[WejaX7zeEBpfW2jbjDFVk1xd3OrdHn2[UBOS0Z5IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yh\XO2cnHkbY9tNWmwZIXj[YQh[2WubDDwdo9tcW[ncnH0bY9vKGG2IEK1NEB1dyB3MECgcm0h[W[2ZYKgOUBl[Xm\|	NHHDSHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlE1PSd-MkS5OFYyPDV:L3G+
MCF7	NE\0bWxHfW6ldHnvckBie3OjeR?=	MWW1JJVO	M2HINFI1KGi{cx?=	M3zveWFvfGGpb37pd5Qh[WO2aY\peJkh[XRiRWLhcJBp[SCrbjDoeY1idiCPQ1[3JINmdGy\|IHHzd4V{e2WmIHHzJJN2eHC{ZYPzbY9vKG:oIF3ZR{BuWk6DIHX4dJJme3Orb36gZZQhPSC3TTDh[pRmeiB{NDDodpMh[nliUVnBfo9tKHKnYXflcpQh[mG\|ZXSgVnQueVCFUjDhcoFtgXOrcx?=	NYHJeYNDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwO\|g3ODlpPkOwNFc5PjB7PD;hQi=>
MCF7	MVnGeY5kfGmxbjDhd5NigQ>?	NUTZephQPSC3TR?=	M{\FSlI1KGi{cx?=	MkKxRY51[WexbnnzeEBi[3Srdnn0fUBifCCHUnHsdIhiKGmwIHj1cYFvKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOgd5VxeHKnc4Ppc44hd2ZiVF\GNUBuWk6DIHX4dJJme3Orb36gZZQhPSC3TTDh[pRmeiB{NDDodpMh[nliUVnBfo9tKHKnYXflcpQh[mG\|ZXSgVnQueVCFUjDhcoFtgXOrcx?=	NE\Rflk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEC3PFYxQSd-M{CwO\|g3ODl:L3G+
MCF7	MVjGeY5kfGmxbjDhd5NigQ>?	MVu1JJVO	NVnuW4lbOjRiaILz	MXrBcpRi\2:waYP0JIFkfGm4aYT5JIF1KEWUYXzwbIEhcW5iaIXtZY4hVUOINzDj[YxteyCjc4Pld5Nm\CCjczDzeZBxemW\|c3nvckBw\iCJUlXCNUBuWk6DIHX4dJJme3Orb36gZZQhPSC3TTDh[pRmeiB{NDDodpMh[nliUVnBfo9tKHKnYXflcpQh[mG\|ZXSgVnQueVCFUjDhcoFtgXOrcx?=	NW\oVI9JRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwO\|g3ODlpPkOwNFc5PjB7PD;hQi=>
MCF7	NHH1PZFHfW6ldHnvckBie3OjeR?=	NVzGXJViPSC3TR?=	MoHtNlQhcHK\|	MlrLRY51[WexbnnzeEBi[3Srdnn0fUBifCCHUnHsdIhiKGmwIHj1cYFvKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOgd5VxeHKnc4Ppc44hd2ZiTWnCUFIhdVKQQTDlfJBz\XO\|aX;uJIF1KDVidV2gZYZ1\XJiMkSgbJJ{KGK7IGHJRZpwdCC{ZXHn[Y51KGKjc3XkJHJVNXGSQ2KgZY5idHm\|aYO=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB5OE[wPUc,OzByN{i2NFk9N2F-
MCF7	MUjGeY5kfGmxbjDhd5NigQ>?	MYC1JJVO	MmX4NlQhcHK\|	NUXRWndGSW62YXfvcol{fCCjY4Tpeol1gSCjdDDFVoFteGijIHnuJIh2dWGwIF3DSlch[2WubIOgZZN{\XO\|ZXSgZZMhe3WycILld5Nqd25ib3[gR2NPTDFibWLORUBmgHC{ZYPzbY9vKGG2IEWgeW0h[W[2ZYKgNlQhcHK\|IHL5JHFKSXqxbDDy[YFo\W62IHLhd4VlKFKWLYHQR3Ih[W6jbInzbZM>	NVroXGJWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwO\|g3ODlpPkOwNFc5PjB7PD;hQi=>
MCF7	M2HHWGZ2dmO2aX;uJIF{e2G7	M3P4W\|UhfU1?	MoL0NlQhcHK\|	MkT2RY51[WexbnnzeEBi[3Srdnn0fUBifCCHUnHsdIhiKGmwIHj1cYFvKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOgd5VxeHKnc4Ppc44hd2ZiQ1TDOkBuWk6DIHX4dJJme3Orb36gZZQhPSC3TTDh[pRmeiB{NDDodpMh[nliUVnBfo9tKHKnYXflcpQh[mG\|ZXSgVnQueVCFUjDhcoFtgXOrcx?=	NEmwfFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEC3PFYxQSd-M{CwO\|g3ODl:L3G+
MCF7	MYfGeY5kfGmxbjDhd5NigQ>?	MWW1JJVO	NWr0b3drOjRiaILz	NGPXcZBCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IFXSZYxxcGFiaX6gbJVu[W5iTVPGO{Bk\WyuczDhd5Nme3OnZDDhd{B{fXCycnXzd4lwdiCxZjDFNmYyKG2UTlGg[ZhxemW\|c3nvckBifCB3IIXNJIFnfGW{IEK0JIhzeyCkeTDRTWF7d2xicnXh[4VvfCCkYYPl[EBTXC2zUFPSJIFv[Wy7c3nz	NF7lc5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEC3PFYxQSd-M{CwO\|g3ODl:L3G+
MCF7	NIHRVWlHfW6ldHnvckBie3OjeR?=	NXj4[XFLPSC3TR?=	NILHfJozPCCqcoO=	MWPBcpRi\2:waYP0JIFkfGm4aYT5JIF1KEWUYXzwbIEhcW5iaIXtZY4hVUOINzDj[YxteyCjc4Pld5Nm\CCjczDzeZBxemW\|c3nvckBw\iCPS1m2O{BuWk6DIHX4dJJme3Orb36gZZQhPSC3TTDh[pRmeiB{NDDodpMh[nliUVnBfo9tKHKnYXflcpQh[mG\|ZXSgVnQueVCFUjDhcoFtgXOrcx?=	NFXMTlc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEC3PFYxQSd-M{CwO\|g3ODl:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-ERK / ERK / p-MEK / MEK1 / MEK2 / p21 / Cyclin D1 ; PubMed: 26163823 Cell Signal LNCaP-Raf:ER cells were treated with increasing doses of 4-hydroxytamoxifen for 2 days. The bottom panel indicates densitometry of MEK1 and MEK2 signals. Data (mean ± standard error) are from two independent experiments. Pearson’s r = 0.823 for MEK1 and −0.673 for MEK2.	26163823
Growth inhibition assay	Cell viability; PubMed: 26014809 Eur J Nutr Dose-dependent effect of 4-hydroxytamoxifen on survival of T47D, MCF-7 and BT-474 cell lines after 96 h of treatment. Control samples were treated with appropriate concentrations of DMSO. Viability was assayed by MTT method.	26014809

Protocol

Cell Research: ^[1]	- Collapse Cell lines: Adult Rat and Mouse Cardiac Myocytes Concentrations: 0, 0.5, 1, 3, 5, and 10 µM Incubation Time: 15-45 min Method: For sarcomere length measurements, cells are covered in Tyrode’s containing 4OHT, allowed to reach 36 ± 1°C, and then stimulated at 0.2 Hz. (Only for Reference)
Animal Research: ^[2]	- Collapse Animal Models: Sprague-Dawley rats Dosages: 21 mg/kg, 54 μmol/kg Administration: oral administration (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	77 mg/mL (198.7 mM)
	Water	Insoluble
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download 4-Hydroxytamoxifen (Afimoxifene) SDF

Molecular Weight	387.51
Formula	C₂₆H₂₉NO₂
CAS No.	68392-35-8
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	Afimoxifene
Smiles	CCC(=C(C1=CC=C(C=C1)O)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03199963	Terminated	Drug: 4-OH tamoxifen\|Drug: Placebo	Mammographic Breast Density	BHR Pharma LLC	August 21 2017	Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Estrogen/progestogen Receptor Signaling Pathway Map

Related Estrogen/progestogen Receptor Products

Licochalcone A ^New

Licochalcone A is an estrogenic flavanoid extracted from licorice root, showing antimalarial, anticancer, antibacterial and antiviral activities. Phase 3.
Endoxifen HCl ^New

Endoxifen HCl, the active metabolite of Tamoxifen, ia a potent and selective estrogen receptor antagonist. Phase 2.
Sacubitril/valsartan (LCZ696) ^New

Sacubitril/valsartan (LCZ696, Sacubitril, Valsartan), consisting of valsartan and sacubitril in 1:1 molar ratio, is an orally bioavailable, dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for hypertension and heart failure. Phase 3.
Fulvestrant (ICI-182780)

Fulvestrant (ICI-182780, ZD 9238, ZM 182780) is an estrogen receptor (ER) antagonist with IC50 of 0.94 nM in a cell-free assay. Fulvestrant also induces autophagy and apoptosis and has antitumor activity.
Tamoxifen (ICI 46474) Citrate

Tamoxifen Citrate (ICI 46474) is a selective estrogen receptor modulator (SERM). Tamoxifen Citrate is also a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen induces apoptosis and autophagy.
Mifepristone (RU486)

Mifepristone (RU486, C-1073, RU 38486, Mifegyne) is a remarkably active antagonist of progesterone receptor and glucocorticoid receptor with IC50 of 0.2 nM and 2.6 nM, respectively. Mifepristone promotes cell autophagy and apoptosis, decreases Bcl-2 level and increases Beclin1 level, accompanied by weakened interaction between Bcl-2 and Beclin1.

Features:Mifepristone is the first approved medication for patients with endogenous cushing's syndrome.
Raloxifene HCl

Raloxifene (LY156758, Keoxifene) HCl a selective and orally active estrogen receptor modulator (SERM), which inhibits human cytosolic aldehyde oxidase-catalyzed phthalazine oxidation activity with IC50 of 5.7 nM.

Features:Raloxifene is as effective as tamoxifen in reducing the incidence of breast cancer in postmenopausal women at increased risk.
Estradiol

Estradiol (17β-estradiol, β-Estradiol, E2, 17β-Oestradiol) is a human sex hormone and steroid, and the primary female sex hormone. Estradiol upregulates IL-6 expression through the estrogen receptor β (ERβ) pathway.
Toremifene Citrate (NK 622)

Toremifene Citrate (NK 622, NSC 613680) is an oral selective estrogen receptor modulator (SERM), used in the treatment of advanced breast cancer.
Progesterone (NSC 9704)

Progesterone (NSC 9704, NSC 64377, Pregn-4-ene-3,20-dione) is an endogenous steroid hormone involved in the menstrual cycle, pregnancy, and embryogenesis of humans and other species. A potent agonist of the nuclear progesterone receptor (nPR) with Kd of 1 nM; An agonist of the membrane progesterone receptors(mPRs); An antagonist of the σ1 receptor.

Choose Your Country or Region

By Signaling Pathways

By product type

4-Hydroxytamoxifen (Afimoxifene)